Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 6:51 PM
Ignite Modification Date:
2025-12-24 @ 6:51 PM
NCT ID:
NCT01535157
Eligibility Criteria:
Inclusion Criteria:
* Recurrent epithelial ovarian cancer or primary peritoneal carcinoma that can be platinum sensitive or platinum resistant
* SWOG Performance Status 0-2
* Previously received a platinum and paclitaxel containing regimen
* Projected Life Expectancy of at least 3 months
* Adequate bone marrow function
* Adequate organ function
* Must have received at least 1 prior salvage regimen for recurrent ovarian cancer
* Recovery from acute toxicities from surgery, radiation or chemotherapy
* At least 3 weeks from last therapy
Exclusion Criteria:
* Prior fenretinide oral capsule use allowed. If prior IV fenretinide use, must contact study chair for eligibility
* Second malignancy within last 5 years
* Use of concomitant antioxidants, such as vitamin C or E
* Untreated or symptomatic brain metastases
* History of hypertriglyceride levels \> 200 mg/dl; triglyceride levels \< 200 and receiving treatment are okay.
* Use of certain medications is prohibited - contact study coordinator for information
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Study:
NCT01535157
Study Brief:
Protocol Section:
NCT01535157